<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="19%"></col>
<col width="81%"></col>
<tbody>
<tr>
<td colspan="2" stylecode="Rrule Botrule Lrule Toprule " valign="middle">
<paragraph>
<content stylecode="bold">Drugs That Interfere with Hemostasis </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>• Naproxen and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of naproxen and anticoagulants has an increased risk of serious bleeding compared to the use of either drug alone. <br/>• Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.  </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Monitor patients with concomitant use of naproxen delayed-release tablets with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding (<content stylecode="italics">see WARNINGS; <linkhtml href="#ID_11986f4c-7c2f-441e-84df-3c4a50da16b4">Hematologic Toxicity</linkhtml>
</content>). </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Aspirin </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone <content stylecode="italics">(see WARNINGS; <linkhtml href="#i4i_section_id_inv-bd543958-6abb-4c1e-b683-71358fc51643">Gastrointestinal Bleeding, Ulceration and Perforation</linkhtml>)</content>. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="bottom">
<paragraph>Concomitant use of naproxen delayed-release tablets and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding (see <content stylecode="italics">WARNINGS; <linkhtml href="#ID_11986f4c-7c2f-441e-84df-3c4a50da16b4">Hematologic Toxicity</linkhtml>). </content>
<br/>Naproxen delayed-release tablets are not a substitute for low dose aspirin for cardiovascular protection. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>• NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol). <br/>• In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>• During concomitant use of naproxen delayed-release tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. <br/>• During concomitant use of naproxen delayed-release tablets and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function (see <content stylecode="italics">WARNINGS; <linkhtml href="#i4i_section_id_inv-6993ee9f-dbe8-4f43-bd64-b7dfc2734d0e">Renal Toxicity and Hyperkalemia</linkhtml>). </content>
<br/>When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Diuretics </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="bottom">
<paragraph>Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>During concomitant use of naproxen delayed-release tablets with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects (see <content stylecode="italics">WARNINGS; <linkhtml href="#i4i_section_id_inv-6993ee9f-dbe8-4f43-bd64-b7dfc2734d0e">Renal Toxicity and Hyperkalemia</linkhtml>). </content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Digoxin </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>The concomitant use of naproxen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>During concomitant use of naproxen delayed-release tablets and digoxin, monitor serum digoxin levels. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Lithium </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="bottom">
<paragraph>NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance<content stylecode="italics">. </content>The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>During concomitant use of naproxen delayed-release tablets and lithium, monitor patients for signs of lithium toxicity. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Methotrexate </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction). </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>During concomitant use of naproxen delayed-release tablets and methotrexate, monitor patients for methotrexate toxicity. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Cyclosporine </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Concomitant use of naproxen delayed-release tablets and cyclosporine may increase cyclosporine’s nephrotoxicity. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>During concomitant use of naproxen delayed-release tablets and cyclosporine, monitor patients for signs of worsening renal function. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">NSAIDs and Salicylates </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Concomitant use of naproxen with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy <content stylecode="italics">(see WARNINGS; <linkhtml href="#i4i_section_id_inv-bd543958-6abb-4c1e-b683-71358fc51643">Gastrointestinal Bleeding, Ulceration and Perforation</linkhtml>). </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Pemetrexed </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Concomitant use of naproxen delayed-release tablets and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information). </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>During concomitant use of naproxen delayed-release tablets and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. <br/>
<br/>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. <br/>
<br/>In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.  </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Antacids and Sucralfate </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Concomitant administration of some antacids (magnesium oxide or aluminum hydroxide) and sucralfate can delay the absorption of naproxen. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Concomitant administration of antacids such as magnesium oxide or aluminum hydroxide, and sucralfate with naproxen delayed-release tablets is not recommended. Due to the gastric pH elevating effects of H2-blockers, sucralfate and intensive antacid therapy, concomitant administration of naproxen delayed-release tablets is not recommended. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Cholestyramine </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>Concomitant administration of cholestyramine can delay the absorption of naproxen. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Concomitant administration of cholestyramine with naproxen delayed-release tablets is not recommended. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Probenecid </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Patients simultaneously receiving naproxen delayed-release tablets and probenecid should be observed for adjustment of dose if required. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="middle">
<paragraph>
<content stylecode="bold">Other albumin-bound drugs </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Naproxen is highly bound to plasma albumin; it thus has a theoretical potential for interaction with other albumin-bound drugs such as coumarin-type anticoagulants, sulphonylureas, hydantoins, other NSAIDs, and aspirin<content stylecode="italics">. </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>Patients simultaneously receiving naproxen delayed-release tablets and a hydantoin, sulphonamide or sulphonylurea should be observed for adjustment of dose if required. </paragraph>
</td>
</tr>
</tbody>
</table>